Impression of Clinical Worsening Fails to Predict Interferon-β Neutralizing Antibody Status
- 1 December 2008
- journal article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 36 (6) , 1418-1425
Abstract
The development of neutralizing antibodies (NAbs) against interferon-β (IFNβ) reduces clinical efficacy and markers of bioactivity in patients with multiple sclerosis (MS), although it has also been shown that a poor response to IFNβ coincided with unexpectedly low NAb levels. To try and resolve this incoherency, this study investigated 2822 patients referred to a NAb testing facility. The reason for NAb testing was indicated for 2506 patients: routine testing (76%), worsening of disease (14%) and other reasons (10%). Overall, 31% of patients were NAb positive and 17% had titres high enough to obliterate IFNβ bioactivity. The frequency of NAbs was similar in patients in the routine testing group compared with the worsening group. Samples showing high titres failed to be associated with worsening of symptoms. The study failed to show low NAb levels in patients responding poorly to IFNβ. It is concluded that it is not possible to predict NAb status by clinical impression of treatment response. This is likely to be an effect of the partial efficacy of IFNβ. Thus routine testing for NAbs must be carried out in order to identify NAb status in patients with MS.Keywords
This publication has 18 references indexed in Scilit:
- Neutralizing Antibodies to Interferon β-1b are not Associated with Disease Worsening in Multiple SclerosisJournal of International Medical Research, 2007
- Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicityMultiple Sclerosis Journal, 2007
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- can the course of multiple sclerosis be modified?Practical Neurology, 2005
- Interferon β-1a in MSNeurology, 2005
- Neutralizing antibodies and efficacy of interferon β-1aNeurology, 2005
- Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisThe Lancet, 2003
- Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patientsNeurology, 2003
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bNeurology, 1996